Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

215 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction in Chinese females

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program

NCT01922193

Infertility

COMPLETED PHASE3

To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation

NCT01029470

Infertility

UNKNOWN PHASE2

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women

NCT03296527

Controlled Ovarian Simulation

COMPLETED PHASE3

Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

NCT03858049

Infertility

TERMINATED PHASE4

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

NCT06173869

Infertility, Female

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anovulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Group

Group Type EXPERIMENTAL

Highly Purified Urofollitropin

Intervention Type DRUG

for Injection

Comparator Group

Group Type ACTIVE_COMPARATOR

Recombinant Human Follitropin Alfa

Intervention Type DRUG

for Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Highly Purified Urofollitropin

for Injection

Intervention Type DRUG

Recombinant Human Follitropin Alfa

for Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bravelle® Gonal-F®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent form prior to screening evaluations
* Chinese females between the ages of 20-39 years
* Infertility for at least 1 year before screening
* Women WHO type II anovulatory infertility with chronic anovulation (defined as amenorrhoea (i.e., no menstrual bleeding for 6 months or more) or oligoamenorrhoea (i.e., cycles of more than 35 days) ) with progestogen induced withdrawal bleeding or spontaneous menstrual bleeding
* Failure to conceive after at least one cycle of ovulation induction with clomiphene citrate
* Bilateral tubal patency documented by a hysterosalpingography or sonohysterography or laparoscopy within 2 years prior to screening
* Normal pelvis documented by a transvaginal ultrasound with respect to uterus, Fallopian tubes and ovaries within 3 months prior to screening
* Early follicular phase serum levels of FSH within normal limits (1-12 IU/L,) (results obtained within 2 months prior to randomization)
* LH (Luteinizing hormone), prolactin , E2 (estradiol), progesteron, total testosterone, and TSH (thyrotropin) levels within normal limits for the clinical laboratory
* Male partner with a semen analysis obtained within 12 months prior to randomisation and showing acceptable values for semen according to the local laboratory, or showing more than 2.000.000 progressive motile sperm per mL after capacitation (in case of IUI (intrauterine insemination))
* BMI (Body mass index) is ≥ 18.5 and \< 30 kg/m2

Exclusion Criteria

* Any known clinically significant systemic disease
* Known past or current thrombophlebitis or thromboembolism including venous thrombosis disease and active or recent arterial thrombosis disease
* Any known endocrine or metabolic abnormalities which can compromise participation in the trial with the exception of controlled thyroid function disease
* Any known concomitant medications that would interfere with evaluation of study medications. Specifically, any non-study hormonal therapy (except for thyroid medication), anti-psychotics, anxiolytics, hypnotics and sedatives, and need for continuous use of prostaglandin inhibitors (non-steroid anti- inflammatory drugs (NSAIDs), including aspirin) at the time of study entry.
* Known history of 12 or more unsuccessful (no pregnancy achieved) ovulation induction cycles
* Any known treatment with clomiphene citrate, metformin, gonadotropins or GnRH analogues within one month prior to randomisation
* Ovarian cysts with a mean diameter ≥ 15 mm that have persisted for more than one cycle or ovarian endometrioma on ultrasound
* Known at least one previous cycle experienced luteinized unruptured follicle syndrome
* Known abnormal results of cervical examination of clinical significance obtained within 1 years prior to screening
* Abnormal vaginal bleeding of undetermined origin
* Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus
* Known malformations of the sexual organs incompatible with pregnancy
* Known current or past (last 12 months) abuse of alcohol or drugs
* Known history of chemotherapy (except for gestational conditions) or radiotherapy
* Finding of any clinically relevant abnormal laboratory value
* Use of any non registered investigational drugs during 3 months before screening or previous participation in the study
* Pregnancy, lactation or contraindication to pregnancy

Minimum Eligible Age

20 Years

Maximum Eligible Age

39 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No